MedTrace Logo

Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

NCT02738905 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2019-02-28

No results posted yet for this study

Summary

The purpose of this study is to determine if rifaximin reduces serum trimethylamine-N-oxide (TMAO) levels in patients with end-stage renal disease.

Conditions

Interventions

DRUG

Rifaximin

One 550 mg tablet taken orally two times a day.

Sponsors & Collaborators

Principal Investigators

  • Jason Stubbs, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2019-02-26
Completion
2019-02-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02738905 on ClinicalTrials.gov